Research and Markets: Keep Up-to-Date on the Progress of the Most Pronounced Anti-Cancer Drugs in Development for Breast Cancer Treatment.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c19799) has announced the addition of Breast Cancer: The Latest R&D Trends to their offering.

In this issue of Cancer Highlights, analysis of the most recent advances made for the mid stage to late stage drugs with breast cancer therapy strategies. This extensive highlight will update you on the progress of the most pronounced anti-cancer drugs in development for breast cancer treatment. We also view the competitive positioning between the already approved and established hormone therapies, which is about to change the standard treatment recommendations.

The breast cancer therapies are dominated by hormone and taxanes, treatments that have been fairly successful. In turn raising the barrier of entrance for novel candidate drugs. Thus affecting the overall rate of clinical success and chance of getting an approval. Because of the complicacy, many companies hold a very low profile in breast cancer R&D, more inclined to announce positive news in other cancer indications. A reason for this might be that unfavorable results have been the reality for many drugs during the most recent years. Most notorious is Genentech's drug Avastin that failed a Phase III study during 2002. Nonetheless, behind the curtain of silence Avastin is still being further studied by other investigators. This phenomenon is true for several other top ranking drugs as well.

In this report we have compiled the most recent information on clinical progress made for the top ranking breast cancer drugs. An analyzes that provide hints on which candidate drugs that has potential to make positive progress and which that is likely to enter a dead end. This study shows that in near term, cytotoxic agents have made significant progression in breast cancer treatment. Advancement has been shown for patients suffering from taxane resistant cancer and in reducing cardiac toxicity in treatment of metastatic breast cancer.

The top new mechanisms that are under investigation include chemopotentiator, protein kinase inhibitors, proteasome inhibitors, farnesyl transferase inhibitors and antisense drugs. Among these new mechanisms a proteinkinase inhibitor has made significant progress and is estimated for New Drug Application in 2005 and Marketing Authorization Application in 2006. Further down the pipe, two farnesyl inhibitors are making good progress. In contrary, the situation for the antisense strategy is a bit shake at the moment.

This report offers:

--A solid background on the latest trends in Breast Cancer therapies.

--The most up-to-date achievements in Breast Cancer treatment.

--A description of new mechanisms under investigation for Breast Cancer therapy 26 industry related R&D Breast Cancer projects in clinical phase II.

--Indications on which projects that are prone to success as well as these who are likely to fail

Topics covered include:

General Working Model & Methodology

Introduction

A Shift in Standard Treatment Recommendations

Clinical Progress of the Established Drugs

Increasing the Competition

Investigational Drugs In Phase II: A challenge or Not?

Appendix A Company Profiles

Appendix B Near Term "Breast Cancer" Progress

Abbreviation List

Companies included in this report:

American Bioscience, AnorMED, AstraZeneca, Biomira Inc, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, GlaxoSmithKline, ISIS Pharmaceuticals, Johnson and Johnson, Lorus Therapeutics, McNeil Pharmaceuticals, Merck KgaA, Millennium Pharmaceuticals, NeoRx, Novartis, OSI Pharmaceuticals, Pfizer, Roche, Salmedix, Schering-Plough and Wyeth.

For more information visit http://www.researchandmarkets.com/reports/c19799